PARP inhibitor-related acute renal failure: a real-world study based on the FDA adverse event reporting system database

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249. doi: 10.3322/caac.21660 Epub 2021 Feb 4. PMID: 33538338.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017 Mar 17;355(6330):1152–1158. doi: 10.1126/science.aam7344 Epub 2017 Mar 16. PMID: 28302823; PMCID: PMC6175050.
   PubMed Web of Science ®Google Scholar
• Boussios S, Karihtala P, Moschetta M, et al. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs. 2020 Feb;38(1):181–193. doi: 10.1007/s10637-019-00867-4 Epub 2019 Oct 24. PMID: 31650446.
   PubMed Web of Science ®Google Scholar
• Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011 Aug;5(4):387–393. doi: 10.1016/j.molonc.2011.07.001 Epub 2011 Jul 22. PMID: 21821475; PMCID: PMC5528309.
   PubMed Web of Science ®Google Scholar
• Aliyuda F, Moschetta M, Ghose A, et al. Advances in ovarian cancer treatment beyond PARP inhibitors. Curr Cancer Drug Targets. 2023;23(6):433–446. doi: 10.2174/1568009623666230209121732 PMID: 36757037.
   PubMed Web of Science ®Google Scholar
• Hatano Y, Tamada M, Matsuo M, et al. Molecular Trajectory of BRCA1 and BRCA2 Mutations. Front Oncol. 2020 Mar 25;10:361. doi: 10.3389/fonc.2020.00361 PMID: 32269964; PMCID: PMC7109296.
   PubMed Web of Science ®Google Scholar
• Garg V, Oza AM. Treatment of ovarian cancer beyond PARP inhibition: current and future options. Drugs. 2023 Oct;83(15):1365–1385. doi: 10.1007/s40265-023-01934-0 Epub 2023 Sep 22. PMID: 37737434; PMCID: PMC10581945.
   PubMed Web of Science ®Google Scholar
• Boussios S, Rassy E, Moschetta M, et al. BRCA mutations in ovarian and prostate cancer: bench to bedside. Cancers (Basel). 2022 Aug 11;14(16):3888. doi: 10.3390/cancers14163888 PMID: 36010882; PMCID: PMC9405840.
   PubMed Web of Science ®Google Scholar
• Mateo J, Lord CJ, Serra V, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019 Sep 1;30(9):1437–1447. doi: 10.1093/annonc/mdz192 PMID: 31218365; PMCID: PMC6771225.
   PubMed Web of Science ®Google Scholar
• Ghose A, Moschetta M, Pappas-Gogos G, et al. Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic. Int J Mol Sci. 2021 Sep 10;22(18):9783. doi: 10.3390/ijms22189783 PMID: 34575947; PMCID: PMC8471942.
   PubMed Web of Science ®Google Scholar
• Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012 Jul 20 [cited 2012 Jun 18];30(21):2654–2663. doi: 10.1200/JCO.2011.39.8545 Erratum in: J Clin Oncol. 2012 Nov 20;30(33):4180. PMID: 22711857; PMCID: PMC3413277.
   PubMed Web of Science ®Google Scholar
• Boussios S, Abson C, Moschetta M, et al. Poly (ADP-Ribose) polymerase inhibitors: Talazoparib in ovarian cancer and beyond. Drugs R D. 2020 Jun;20(2):55–73. doi: 10.1007/s40268-020-00301-8 PMID: 32215876; PMCID: PMC7221042.
   PubMed Web of Science ®Google Scholar
• Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020 Mar 1;34(5–6):360–394. doi: 10.1101/gad.334516.119 Epub 2020 Feb 6. PMID: 32029455; PMCID: PMC7050487.
   PubMed Web of Science ®Google Scholar
• Zhao D, Long X, Wang J. Metabolism related pharmacokinetic drug drug interactions with poly (ADPribose) polymerase inhibitors (Review). Oncol Rep. 2022 Jan;47(1):20. doi: 10.3892/or.2021.8231 Epub 2021 Nov 23. PMID: 34812476.
   PubMed Web of Science ®Google Scholar
• Zhao D, Long X, Wang J. Dose adjustment of Poly (ADP‑Ribose) polymerase inhibitors in patients with hepatic or renal impairment. DDDT. 2022 Nov 14;16:3947–3955. doi: 10.2147/DDDT.S387920 PMID: 36405648; PMCID: PMC9673935.
   PubMed Web of Science ®Google Scholar
• Rolfo C, de Vos-Geelen J, Isambert N, et al. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and renal impairment. Clin Pharmacokinet. 2019 Sep;58(9):1165–1174. doi: 10.1007/s40262-019-00754-4 PMID: 30877569.
   PubMed Web of Science ®Google Scholar
• Salem AH, Giranda VL, Mostafa NM. Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies. Clin Pharmacokinet. 2014 May;53(5):479–488. doi: 10.1007/s40262-013-0130-1 PMID: 24452810.
   PubMed Web of Science ®Google Scholar
• Oza AM, Tinker AV, Oaknin A, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017 Nov;147(2):267–275. doi: 10.1016/j.ygyno.2017.08.022 Epub 2017 Sep 4. PMID: 28882436.
   PubMed Web of Science ®Google Scholar
• Li N, Zhu J, Yin R, et al. Treatment with Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2023 Sep 1;9(9):1230–1237. doi: 10.1001/jamaoncol.2023.2283 PMID: 37440217; PMCID: PMC10346505.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al. ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017 Oct 28;390(10106):1949–1961. doi: 10.1016/S0140-6736(17)32440-6 Epub 2017 Sep 12. Erratum in: Lancet. 2017 Oct 28;390(10106):1948. PMID: 28916367; PMCID: PMC5901715.
   PubMed Web of Science ®Google Scholar
• LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019 Jan;20(1):e15–e28. doi: 10.1016/S1470-2045(18)30786-1 PMID: 30614472; PMCID: PMC7292736.
   PubMed Web of Science ®Google Scholar
• Friedlander M, Lee YC, Tew WP. Managing adverse effects associated with Poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data. Am Soc Clin Oncol Educ Book. 2023 Jun;43:e390876. doi: 10.1200/EDBK_390876 PMID: 37285556.
   PubMedGoogle Scholar
• US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) quarterly data extract files. 2021 [cited 2021 Oct 20]. Available from: https://fis.fda.gov/extensions/fpd-qde-faers/fpd-qde-faers.html
   Google Scholar
• Maintenance and support service organization. Support documentation: MedDRA Version 23.0 English March/April 2020. [cited 2021 Oct 6]. Available from: https://www.meddra.org/how-to-use/support-documentation/English
   Google Scholar
• Bräuer D. Zum Vergleich unabhängiger Stichproben. Comparison of independent samples: the Kruskal-Wallis test and the Conover multiple median value comparison. Z Arztl Fortbild (Jena). 1988;82(18):883–884. German. PMID: 3213086.
   PubMedGoogle Scholar
• O’Malley DM, Krivak TC, Kabil N, et al. PARP inhibitors in ovarian cancer: a review. Target Oncol. 2023 Jul;18(4):471–503. doi: 10.1007/s11523-023-00970-w Epub 2023 Jun 3. PMID: 37268756; PMCID: PMC10344972.
   PubMed Web of Science ®Google Scholar
• Giannini A, Di Dio C, Di Donato V, et al. PARP inhibitors in newly diagnosed and recurrent ovarian cancer. Am J Clin Oncol. 2023 Sep 1;46(9):414–419. doi: 10.1097/COC.0000000000001024 Epub 2023 Jun 12. PMID: 37314974.
   PubMed Web of Science ®Google Scholar
• Fischetti M, Di Donato V, Palaia I, et al. Advances in small molecule maintenance therapies for high-grade serous ovarian cancer. Expert Opin Pharmacother. 2023 Jan;24(1):65–72. doi: 10.1080/14656566.2022.2154144 Epub 2022 Dec 12. PMID: 36458890.
   PubMed Web of Science ®Google Scholar
• Golia D’Augè T, Giannini A, Bogani G, et al. Treatment and follow-up of gynecological cancers: state of art and future perspectives. Clin Exp Obstet Gynecol. 2023;50(8):160. doi: 10.31083/j.ceog5008160
   Web of Science ®Google Scholar
• Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med. 1988;39:465–490. doi: 10.1146/annurev.me.39.020188.002341 PMID: 3285786.
   PubMed Web of Science ®Google Scholar
• Colombi A. Die klinische Bedeutung der Nierenfunktionsprüfungen [The clinical significance of kidney function tests]. Schweiz Med Wochenschr. 1989 Jun 17;119(24):854–858. German. PMID: 2749216.
   PubMedGoogle Scholar
• Nakada T, Kudo T, Kume T, et al. Estimation of changes in serum creatinine and creatinine clearance caused by renal transporter inhibition in healthy subjects. Drug Metab Pharmacokinet. 2019 Aug;34(4):233–238. doi: 10.1016/j.dmpk.2019.02.006 Epub 2019 Mar 2. PMID: 31176593.
   PubMed Web of Science ®Google Scholar
• Nigam SK. What do drug transporters really do? Nat Rev Drug Discov. 2015 Jan;14(1):29–44. doi: 10.1038/nrd4461 Epub 2014 Dec 5. PMID: 25475361; PMCID: PMC4750486.
   PubMed Web of Science ®Google Scholar
• Zhao D, Long X, Wang J. Transporter mediated drug drug interactions involving poly (ADPribose) polymerase inhibitors (Review). Oncol Lett. 2023 Mar 7;25(4):161. doi: 10.3892/ol.2023.13747 PMID: 36936025; PMCID: PMC10017913.
   PubMed Web of Science ®Google Scholar
• Rives ML, Javitch JA, Wickenden AD. Potentiating SLC transporter activity: Emerging drug discovery opportunities. Biochem Pharmacol. 2017 Jul 1;135:1–11. doi: 10.1016/j.bcp.2017.02.010 Epub 2017 Feb 16. PMID: 28214518.
   PubMed Web of Science ®Google Scholar
• Beis K. Structural basis for the mechanism of ABC transporters. Biochem Soc Trans. 2015 Oct;43(5):889–893. doi: 10.1042/BST20150047 PMID: 26517899.
   PubMedGoogle Scholar
• Yonezawa A, Inui K. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br J Pharmacol. 2011 Dec;164(7):1817–1825. doi: 10.1111/j.1476-5381.2011.01394.x PMID: 21457222; PMCID: PMC3246706.
   PubMed Web of Science ®Google Scholar
• Samodelov SL, Kullak-Ublick GA, Gai Z, et al. Organic cation transporters in human physiology, pharmacology, and toxicology. Int J Mol Sci. 2020 Oct 24;21(21):7890. doi: 10.3390/ijms21217890 PMID: 33114309; PMCID: PMC7660683.
   PubMed Web of Science ®Google Scholar
• Pochini L, Galluccio M, Scalise M, et al. OCTN: a small transporter subfamily with great relevance to human pathophysiology, drug discovery, and diagnostics. SLAS Discov. 2019 Feb;24(2):89–110. doi: 10.1177/2472555218812821 Epub 2018 Dec 7. PMID: 30523710.
   PubMed Web of Science ®Google Scholar
• Nies AT, Damme K, Kruck S, et al. Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine. Arch Toxicol. 2016 Jul;90(7):1555–1584. doi: 10.1007/s00204-016-1728-5 Epub 2016 May 10. PMID: 27165417.
   PubMed Web of Science ®Google Scholar
• Motohashi H, Inui K. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. Aaps J. 2013 Apr;15(2):581–588. doi: 10.1208/s12248-013-9465-7 Epub 2013 Feb 22. PMID: 23435786; PMCID: PMC3675737.
   PubMed Web of Science ®Google Scholar
• Brecht K, Schäfer AM, Meyer Zu Schwabedissen HE. Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in anticancer therapy-modulators of cellular entry or pharmacokinetics? Cancers (Basel). 2020 Aug 12;12(8):2263. doi: 10.3390/cancers12082263 PMID: 32806706; PMCID: PMC7464370.
   PubMed Web of Science ®Google Scholar
• Mathialagan S, Rodrigues AD, Feng B. Evaluation of renal transporter inhibition using creatinine as a substrate in vitro to assess the clinical risk of elevated serum creatinine. J Pharm Sci. 2017 Sep;106(9):2535–2541. doi: 10.1016/j.xphs.2017.04.009 Epub 2017 Apr 14. PMID: 28416419.
   PubMed Web of Science ®Google Scholar
• Tew WP, Lacchetti C, Ellis A, et al. PARP Inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol. 2020 Oct 20;38(30):3468–3493. doi: 10.1200/JCO.20.01924 Epub 2020 Aug 13. PMID: 32790492; PMCID: PMC8942301.
   PubMed Web of Science ®Google Scholar
• Rose M, Burgess JT, O’Byrne K, et al. PARP Inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020 Sep 9;8:564601. doi: 10.3389/fcell.2020.564601 PMID: 33015058; PMCID: PMC7509090.
   PubMed Web of Science ®Google Scholar
• Hennes ER, Dow-Hillgartner EN, Bergsbaken JJ, et al. PARP-inhibitor potpourri: a comparative review of class safety, efficacy, and cost. J Oncol Pharm Pract. 2020 Apr;26(3):718–729. doi: 10.1177/1078155219895066 Epub 2020 Jan 6. PMID: 31902284.
   PubMed Web of Science ®Google Scholar
• Martins Ml F, Loos NHC, Mucuk S, et al. P-Glycoprotein (ABCB1/MDR1) controls brain penetration and intestinal disposition of the PARP1/2 inhibitor Niraparib. Mol Pharm. 2021 Dec 6;18(12):4371–4384. doi: 10.1021/acs.molpharmaceut.1c00553 Epub 2021 Nov 3. PMID: 34730366.
   PubMedGoogle Scholar
• Durmus S, Sparidans RW, van Esch A, et al. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res. 2015 Jan;32(1):37–46. doi: 10.1007/s11095-014-1442-z Epub 2014 Jun 25. PMID: 24962512.
   PubMed Web of Science ®Google Scholar
• Dufour R, Daumar P, Mounetou E, et al. BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib. Sci Rep. 2015 Aug 3;5:12670. doi: 10.1038/srep12670 PMID: 26234720; PMCID: PMC4522660.
   PubMed Web of Science ®Google Scholar
• McCormick A, Swaisland H. In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib. Xenobiotica. 2017 Oct;47(10):903–915. doi: 10.1080/00498254.2016.1241449 Epub 2016 Oct 26. PMID: 27684210.
   PubMed Web of Science ®Google Scholar
• Bruin MAC, Korse CM, van Wijnen B, et al. A real or apparent decrease in glomerular filtration rate in patients using olaparib? Eur J Clin Pharmacol. 2021 Feb;77(2):179–188. doi: 10.1007/s00228-020-03070-0 Epub 2020 Dec 14. PMID: 33319340; PMCID: PMC7803870.
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Fujiwara M, Uchida M, et al. Comprehensive analysis of adverse events induced by PARP inhibitors using JADER and time to onset. Life (Basel). 2022 Aug 31;12(9):1355. doi: 10.3390/life12091355 PMID: 36143391; PMCID: PMC9504973.
   PubMed Web of Science ®Google Scholar
• Lazareth H, Delanoy N, Cohen R, et al. Nephrotoxicity associated with Niraparib. Am J Kidney Dis. 2020 Dec;76(6):898–900. doi: 10.1053/j.ajkd.2020.05.021 Epub 2020 Jul 14. PMID: 32679152.
   PubMed Web of Science ®Google Scholar
• Bruin MAC, Sonke GS, Beijnen JH, et al. Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology. Clin Pharmacokinet. 2022 Dec;61(12):1649–1675. doi: 10.1007/s40262-022-01167-6 Epub 2022 Oct 11. PMID: 36219340; PMCID: PMC9734231.
   PubMed Web of Science ®Google Scholar
• Liao M, Jaw-Tsai S, Beltman J, et al. Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor. Xenobiotica. 2020 Sep;50(9):1032–1042. doi: 10.1080/00498254.2020.1737759 Epub 2020 Mar 18. PMID: 32129697.
   PubMed Web of Science ®Google Scholar
• Zibetti Dal Molin G, Westin SN, Msaouel P, et al. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer. 2020 Jan;30(1):89–93. doi: 10.1136/ijgc-2019-000714 Epub 2019 Dec 1. PMID: 31792084.
   PubMed Web of Science ®Google Scholar